Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc.

Summary

Classen Immunotherapies sued Elan Pharmaceuticals for patent infringement in federal court. The case involves patents related to immunotherapy technology, with John Barthelow Classen listed as a counterclaim defendant. The suit centers on whether Elan's products or methods infringe Classen's patent rights.

Summary generated by AI from public docket data. Verify against the original filing before relying on it.

Coverage vs reality meter

Entities in this case

Parties

CLASSEN IMMUNOTHERAPIES, INC., a Maryland corporation (plaintiff) ELAN PHARMACEUTICALS, INC., a Delaware corporation (defendant) JOHN BARTHELOW CLASSEN (counterclaim defendant)

Docket entries

1. #432018-06-12

   The petition for writ of certiorari, [17-1409], filed on 03/26/2018, was Denied on 06/11/2018. [528600] [JAB] [Entered: 06/12/2018 08:51 AM]

2. #422018-04-18

   Petition for writ of Certiorari filed on 03/26/2018, and placed on the docket 04/10/2018, in the Supreme Court of the United States. Supreme Court #: 17-1409, Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc. [514907] [JAB] [Entered: 04/18/2018 02:20 PM]

3. #412018-04-11

   Petition for writ of Certiorari filed on 01/16/2018, and placed on the docket 04/10/2018, in the Supreme Court of the United States. Supreme Court #: 17-1409, Classen Immunotherapies, Inc. v. Elan Pharmaceuticals, Inc. [512578] [JAB] [Entered: 04/11/2018 03:42 PM]

4. #402017-11-27

   Mandate issued to the United States District Court for the District of Maryland. Costs taxed in the amount of $251.76. Service as of this date by Clerk of Court. [478181] [JAB] [Entered: 11/27/2017 12:39 PM]

5. #392017-10-31

   Bill of Costs for Appellee Elan Pharmaceuticals, Inc.. Service: 10/31/2017 by email. Objection to Bill of Costs due on 11/14/2017. [471938] [James Monroe] [Entered: 10/31/2017 01:41 PM]

6. #382017-10-17

   OPINION and JUDGMENT filed. The judgment or decision is: Affirmed. (FCR 36). (For the Court: Prost,Chief Judge; Lourie,Circuit Judge and Taranto,Circuit Judge). [468265] [JAB] [Entered: 10/17/2017 09:32 AM]

7. #372017-10-04

   Submitted after ORAL ARGUMENT by Joseph J. Zito for Classen Immunotherapies, Inc. and James B. Monroe for Elan Pharmaceuticals, Inc. Panel: Judge: Prost, Judge: Lourie, Judge: Taranto. [465514] [JAB] [Entered: 10/04/2017 12:53 PM]

8. #362017-09-15

   Response to oral argument order from the Appellee Elan Pharmaceuticals, Inc.. designating James B. Monroe as arguing attorney. Designated time for argument: 15 minutes. Designated time for rebuttal: 0 minutes. Service of other counsel by Notice of Docket Activity from this entry. [461292] [James Monroe] [Entered: 09/15/2017 12:29 PM]

9. #352017-09-11

   Response to oral argument order from the Appellant Classen Immunotherapies, Inc.. designating Joseph J. Zito as arguing attorney. Designated time for argument: 10 minutes. Designated time for rebuttal: 5 minutes. Service of other counsel by Notice of Docket Activity from this entry. [460111] [Joseph Zito] [Entered: 09/11/2017 01:04 PM]

10. #342017-08-21

    NOTICE OF CALENDARING. Panel: 1710C. Case scheduled Oct 04, 2017 10:00 a.m. at the U.S. Court of Appeals for the Second Circuit (40 Foley Square, New York, NY 10007), Courtroom 1505. Response to oral argument order due: 09/15/2017. Counsel should check-in 30 minutes prior to the opening of the session. Please review the Oral Argument Order. [455494] [JAB] [Entered: 08/21/2017 03:43 PM]

11. #332017-04-12

    Notice from Appellee Elan Pharmaceuticals, Inc. regarding conflicts with oral argument (May 1-5 & 8, 2017; June 5 & 9, 2017; July 10 & 11, 2017). Service: 04/12/2017 by email. [423511] [James Monroe] [Entered: 04/12/2017 02:34 PM]

12. #322017-04-06

    6 paper copies of the Joint Appendix [29] received from Appellant Classen Immunotherapies, Inc. [422162] [KW] [Entered: 04/06/2017 03:04 PM]

13. #312017-04-05

    Pursuant to Practice Note 34, counsel should advise the clerk of court of scheduling conflicts for the next three court weeks, or thereafter. When filing the notice of conflicts, counsel should docket the Notice Regarding Conflicts with Argument Dates event, which is found in the Calendar event category. The notice of conflict with oral argument is due on or before 04/12/2017. [421646] [CAB] [Entered: 04/05/2017 12:13 PM]

14. #302017-04-05

    CLERK'S OFFICE QUALITY CONTROL MESSAGE: ERROR: Portions of the Joint Appendix [29] were not text-searchable. CORRECTION: All submissions to the court are required to be text-searchable in their entirety. Please ensure future filings are text-searchable. THIS MESSAGE IS FOR INFORMATIONAL PURPOSES ONLY. [421638] [MJL] [Entered: 04/05/2017 11:49 AM]

15. #292017-03-30

    APPENDIX FILED for Classen Immunotherapies, Inc. [27]. Number of Pages: 164. Service: 03/30/2017 by email. The paper copies of the appendix should be received by the court on or before 04/12/2017. [421636] [MJL] [Entered: 04/05/2017 11:46 AM]

16. #282017-03-30

    Certificate of Compliance with Fed. Cir. R. 11(d) (Trial Court) for Appellee Elan Pharmaceuticals, Inc.. Service: 03/30/2017 by email. [420511] [James Monroe] [Entered: 03/30/2017 07:30 PM]

17. #272017-03-30

    TENDERED from Appellant Classen Immunotherapies, Inc.. Title: JOINT APPENDIX. Service: 03/30/2017 by email. [420467] [Joseph Zito] [Entered: 03/30/2017 04:32 PM]

18. #262017-03-28

    6 paper copies of the Reply Brief [25] received from Appellant Classen Immunotherapies, Inc. [419531] [KW] [Entered: 03/28/2017 01:29 PM]

19. #1309582492017-03-09

    TENDERED from Appellee Elan Pharmaceuticals, Inc.. Title: RESPONSE BRIEF. Service: 03/09/2017 by email. [414176]

20. 2017-01-13

    Clerk Order Filed

Docket history from CourtListener/RECAP — most recent first.